Inactive Instrument

Correvio Pharma Corp Stock price Toronto S.E.

Equities

CA14159U3010

Pharmaceuticals

Sales 2018 28.67M 38.89M Sales 2019 32.63M 44.27M Capitalization 27.28M 37.01M
Net income 2018 -16M -21.7M Net income 2019 -35M -47.48M EV / Sales 2018 5.13 x
Net Debt 2018 25.92M 35.16M Net Debt 2019 33.9M 45.99M EV / Sales 2019 1.87 x
P/E ratio 2018
-7.1 x
P/E ratio 2019
-0.68 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 86.23%
More Fundamentals * Assessed data
Dynamic Chart
Members of the board TitleAgeSince
Director/Board Member - -
Director/Board Member 53 -
Director/Board Member - -
More insiders
Correvio Pharma Corp is a Canada-based company, which is a specialty pharmaceutical company. The Company focused on providing acute services. It's portfolio brands includes: Xydalba (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. The Company's products include Trevyent, a drug-device combination that is designed to deliver treprostinil, the treatment for pulmonary arterial hypertension.
More about the company
  1. Stock
  2. Equities
  3. Stock Correvio Pharma Corp.
  4. Stock Correvio Pharma Corp - Toronto S.E.